Search company, investor...

Founded Year



Reverse Merger | IPO

Total Raised


Market Cap


Stock Price


About Roivant Sciences

Roivant Sciences is a company focused on the biotechnology and healthcare technology sectors. The company's main services include the discovery, development, and commercialization of innovative medicines and technologies, which are carried out by its agile, focused subsidiaries known as 'Vants'. These products primarily cater to the healthcare industry, targeting a wide range of diseases. It was founded in 2014 and is based in New York, New York.

Headquarters Location

151 W 42nd Street 15th Floor

New York, New York, 10036,

United States



Expert Collections containing Roivant Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Roivant Sciences is included in 1 Expert Collection, including Artificial Intelligence.


Artificial Intelligence

10,958 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.

Roivant Sciences Patents

Roivant Sciences has filed 6 patents.

The 3 most popular patent topics include:

  • amines
  • hepatology
  • piperidines
patents chart

Application Date

Grant Date


Related Topics




Hepatology, Stimulants, Amines, Transcription factors, Piperidines


Application Date


Grant Date



Related Topics

Hepatology, Stimulants, Amines, Transcription factors, Piperidines



Latest Roivant Sciences News

Roivant Sciences shares drop as lupus trial misses goal

Nov 28, 2023

27-11-2023 Roivant Sciences’ (Nasdaq: ROIV) shares fell 4.7% to $8.70 in early morning trading yesterday, after it announced the Phase II study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of systemic lupus erythematosus responder index change of 4 (SRI-4) at Week 52. Priovant plans to disclose the study data at a future date. Priovant to continue development Priovant Therapeutics,… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

Roivant Sciences Frequently Asked Questions (FAQ)

  • When was Roivant Sciences founded?

    Roivant Sciences was founded in 2014.

  • Where is Roivant Sciences's headquarters?

    Roivant Sciences's headquarters is located at 151 W 42nd Street, New York.

  • What is Roivant Sciences's latest funding round?

    Roivant Sciences's latest funding round is Reverse Merger.

  • How much did Roivant Sciences raise?

    Roivant Sciences raised a total of $2.5B.

  • Who are the investors of Roivant Sciences?

    Investors of Roivant Sciences include Montes Archimedes Acquisition, Palantir, SK Holdings, Sumitomo Dainippon Pharma, SoftBank and 6 more.

  • Who are Roivant Sciences's competitors?

    Competitors of Roivant Sciences include Redesign Science and 4 more.


Compare Roivant Sciences to Competitors

Insitro Logo

Insitro provides data-driven drug discovery and development solutions. It combines machine learning and modern biological tools to enable predictive models. The company was founded in 2018 and is based in South San Francisco, California.

Google Cloud Platform Logo
Google Cloud Platform

Google Cloud Platform, offered by Google, is a suite of cloud computing services that runs on the same infrastructure that Google uses internally for its end-user products.

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine operates as a clinical-stage biotechnology company operating in pharmaceutical research and development. It offers services that include novel target discovery, generation of molecular structures with desired properties, and clinical trial analysis, enabled by advanced machine learning techniques. Its services primarily cater to the healthcare industry, with a particular emphasis on the discovery and development of innovative drugs for a range of conditions including cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It was founded in 2014 and is based in New Territories, Hong Kong.

Acellera Logo

Acellera is a technology company that focuses on computable drug discovery in the pharmaceutical industry. The company offers services and solutions for drug discovery, including target-validation, hit-identification, hit-to-lead and lead optimization, and also provides software platforms for biomolecular molecular simulation and computable drug discovery. Acellera primarily sells to the pharmaceutical and academic sectors. It was founded in 2006 and is based in Barcelona, Spain.

Atomwise Logo

Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.

XtalPi Logo

XtalPi provides quantum physic-based artificial intelligence (AI) for drug research and development. It offers accurate predictions on the physicochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi was founded in 2014 and is based in Shenzhen, China.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.